V. Levy and M. Robert, “Antiretroviral Therapy for Hepatitis B Virus-HIV Co-Infected Patients: Promises and Pitfalls,” Clinical Infectious Diseases, Vol. 43, No. 10, 2006, pp. 904-910. http://dx.doi.org/10.1086/507532
 H. L. Omland, et al., “Impact of Hepatitis B Virus CoInfection on Response to Highly Active Antiretroviral Treatment and Outcome in HIV-Infected Individuals: A Nationwide Cohort Study,” British HIV Association HIV Medicine, Vol. 9, No. 5, 2008, pp. 300-306.
 K. Lacombe, et al., “HIV/Hepatitis B Virus Co-Infection: Current Challenges and New Strategies,” Journal of Antimicrobial Chemotherapy, Vol. 65, No. 1, 2010, pp. 10-17.
 S. Kenneth, P. Marion and K. Margaret, “HIV and Liver Disease Forum: Conference Proceedings,” Hepatology, Vol. 45, No. 6, 2007, pp. 1566-1577.
 C. J. Hoffmann and C. L. Thio, “Clinical Implications of HIV and Hepatitis B Co-Infection in Asia and Africa,” The Lancet Infectious Diseases, Vol. 7, No. 6, 2007, pp. 402-409.
 M. Gomez-Gonzalo, M. Carretero and J. Rullas, “The Hepatitis B Virus X Protein Induces HIV-1 Replication and Transcription in Synergy with T-Cell Activation Signals,” The Journal of Biological Chemistry, Vol. 38, 1976, pp. 35435-35443.
 V. Soriano, et al., “Care of HIV Patients with Chronic Hepatitis B: Updated Recommendations from the HIVHepatitis B Virus International Panel,” AIDS, Vol. 22, No. 12, 2008, pp. 1399-1410.
 V. DiMartino, “Influence of HIV Infection on the Response to Interferon Therapy and the Long Term Outcome of Chronic Hepatitis B,” Gastroenterology, Vol. 123, No. 6, 2002, pp. 1812-1822.
 R. K. Sterling, “Hepatitis B Virus in the Setting of HIV Infection: A Clinical Challenge. Medical Writers’ Circle,” 2003. http://www.hcvadvocate.org/hcsp/board.asp
 A. DeLuca, R. Bugarini and A. C. Lepri, “Co-Infection with Hepatitis Viruses and Outcome of Initial Antiretroviral Regimens in Previously Naive HIV-Infected Subjects,” Archives of Internal Medicine, Vol. 162, No. 18, 2002, pp. 2125-2132.
 J. Idoko, S. Meloni and M. Muazu, “Hepatitis B virus CoInfection Impacts Baseline HIV Parameters and HAARTRelated Hepatotoxicity Risk in an HIV-Infected Nigerian Cohort,” 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, 25-28 February 2007.
 C. L. Thio, et al., “HIV-1, Hepatitis B Virus, and Risk of Liver Related Mortality in the Multicenter Cohort Study (MACS),” Lancet, Vol. 360, No. 9349, 2002, pp. 1921-1926.
 T. Wilkin, “What Causes Poor CD4-Cell Recovery in the Setting of Suppressive Antiretroviral Therapy?” Journal Watch HIV/AIDS Clinical Care, 2010.
 J. J. Chang, et al., “Reduced Hepatitis B Virus (HBV)Specific CD4_ T-Cell Responses in Human Immunodeficiency Virus Type 1-HBV-Coinfected Individuals Receiving HBV-Active Antiretroviral Therapy,” Journal of Virology, Vol. 79, No. 5, 2005, pp. 3038-3051.
 M. Crane, S. Sirivichayakul and J. J. Chang, “No Increase in Hepatitis B Virus (HBV)-Specific CD8-T Cells in Patients with HIV-1-HBV Co-Infections Following HBVActive HAART,” Journal of Virology, Vol. 84, No. 6, 2010, pp. 2657-2665.
 S. Mauss, et al., “Hepatology: A Clinical Textbook,” Flying Publisher, Germany, 2009.
 Y. Benhamou, M. Bochet and V. Thibault, “Long-Term Incidence of Hepatitis B Virus Resistance to Lamivudine in Human Immunodeficiency Virus-Infected Patients,” Hepatology, Vol. 30, No. 5, 1999, pp. 1302-1306.